Re­lay builds out case for an­ti-FGFR drug, shoot­ing for first ac­cel­er­at­ed ap­proval on 'mo­tion-based' drug dis­cov­ery plat­form

Last Oc­to­ber, Re­lay Ther­a­peu­tics re­vealed ear­ly da­ta for its lead pro­gram, RLY-4008, hop­ing to build a case around a dif­fer­en­ti­at­ed safe­ty pro­file. Ear­ly Mon­day morn­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER